Showing results (81-90 of 99) with videos related to

Sort By:
Pageof 10
Journal of Learning Disabilities|July 26, 2024
Do Mathematics and Reading Skills Impact Student Science Outcomes?Christian T Doabler, Megan Rojo, Jenna A Gersib, et al.
Microorganisms|May 28, 2022
Loop-Mediated Isothermal Amplification of Trypanosoma cruzi DNA for Point-of-Care Follow-Up of Anti-Parasitic Treatment of Chagas DiseaseArturo A Muñoz-Calderón, Susana A Besuschio, Season Wong, et al.
Acta Oncologica (Stockholm, Sweden)|March 14, 2018
Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patientsE Palmerini, R L Jones, E Setola, et al.
BMC Cancer|September 26, 2023
IDH mutations in G2-3 conventional central bone chondrosarcoma: a mono institutional experienceElisabetta Setola, S Benini, A Righi, et al.
Bioorganic & Medicinal Chemistry Letters|February 20, 2008
Optimization of 1H-tetrazole-1-alkanenitriles as potent orally bioavailable growth hormone secretagoguesAndrés S Hernández, Stephen G Swartz, Dorothy Slusarchyk, et al.
Plos Neglected Tropical Diseases|August 16, 2020
Trypanosoma cruzi loop-mediated isothermal amplification (Trypanosoma cruzi Loopamp) kit for detection of congenital, acute and Chagas disease reactivationSusana A Besuschio, Albert Picado, Arturo Muñoz-Calderón, et al.
Bioorganic & Medicinal Chemistry Letters|September 18, 2007
Discovery, synthesis, and structure-activity studies of tetrazole based growth hormone secretagoguesAndrés S Hernández, Peter T W Cheng, Christa M Musial, et al.
European Journal of Cancer (Oxford, England : 1990)|February 8, 2017
Extraskeletal osteosarcoma: A European Musculoskeletal Oncology Society study on 266 patientsA Longhi, S S Bielack, R Grimer, et al.
Memorias Do Instituto Oswaldo Cruz|May 26, 2016
Serological based monitoring of a cohort of patients with chronic Chagas disease treated with benznidazole in a highly endemic area of northern ArgentinaLeticia L Niborski, Vanina Grippo, Sonia O Lafón, et al.
ESMO Open|September 25, 2021
Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050)☆N Gaspar, Q Campbell-Hewson, S Gallego Melcon, et al.
Pageof 10